Inactivation of Drug Metabolism and Therapy with connections to Mitochondrial Toxicity in Global Chronic Diseases

Research output: Contribution to conferenceAbstract

Abstract

Prevalent chronic diseases such as cardiovascular disease, non alcoholic fatty liver disease (NAFLD) and neurodegenerative diseases that includes epilepsy induced stroke have raised major concern with relevance to diabetes and the global problem for chronic diseases. The need to optimize drug therapy and improve therapeutic outcomes has become of major concern with relevance to alarming reports of drug-drug interactions or drug-protein interactions. The role of various factors such as diet, environment, stress and lifestyle as important factors that regulate drug therapy and stabilize insulin resistance is relevant to chronic diseases. Research that involves the various factors and inactivation of anti-aging genes have indicated relevance to defective drug metabolism. The heat shock gene Sirtuin 1 (Sirt 1) and its repression inactivates insulin therapy and hepatic drug metabolism with inactivation of antimicrobial therapy. Sirt 1 inhibitors are connected to mitophagy and induction of NAFLD linked to food quality and pharmacological management (antimicrobial/antiepileptic therapy). Drug such as Avasimibe reverse NAFLD and improve pharmacological management in NAFLD and chronic diseases.

Original languageEnglish
Publication statusPublished - 28 Aug 2018
Event10th World Congress on Neuropharmacology, - Paris , France
Duration: 28 Aug 201829 Aug 2018

Conference

Conference10th World Congress on Neuropharmacology,
CountryFrance
CityParis
Period28/08/1829/08/18

Fingerprint Dive into the research topics of 'Inactivation of Drug Metabolism and Therapy with connections to Mitochondrial Toxicity in Global Chronic Diseases'. Together they form a unique fingerprint.

  • Cite this

    Martins, I. (2018). Inactivation of Drug Metabolism and Therapy with connections to Mitochondrial Toxicity in Global Chronic Diseases. Abstract from 10th World Congress on Neuropharmacology, , Paris , France.